Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

GHBullishIndustry Newsnews

High materiality7/10

Guardant Health Uses Dempsey Campaign to Drive Shield CRC Testing Adoption

Jul 28, 2026, 7:15 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive exposure from a high-profile campaign and continued alignment with major guidelines could lift testing volumes and revenue, especially if uptake translates to higher Shield orders in 6–12 months.

AI summary

What happened, with direct paths to the underlying reporting

Guardant Health promotes its Shield blood test for colorectal cancer via a Patrick Dempsey video, highlighting FDA approval and guideline inclusion. With ACS updates in 2026 favoring blood-based screening and real-world Shield completion above 90% across over 1 million tests, the campaign could lift near-term screening adoption and Shield demand.

Guardant Health launches Patrick Dempsey video to promote Shield CRC screening.
Shield is the only FDA-approved blood test in ACS and NCCN CRC guidelines.
Shield has performed over 1,000,000 tests with >90% real-world completion.
ACS 2026 updates emphasize blood-based and at-home screening options.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Guardant Health Uses Dempsey Campaign to Drive Shield CRC Testing Adoption

Guardant Health Faces $245M+ Damages Verdict in Duplex Sequencing Case

Guardant Shield gains ACS guideline inclusion, broadening colorectal cancer screening access

Guardant Health's New Liquid Biopsy Receives FDA Approval

Guardant Health shares decline amid FDA review of AstraZeneca's breast cancer drug